Search This Blog

Thursday, December 3, 2020

Enlivex up on interim Allocetra data in mid-stage COVID-19 study

 

  • Enlivex Therapeutics (NASDAQ:ENLV) jumps 35% in premarket, in reaction to announcement of interim data from Phase 2 trial evaluating Allocetra in severe/critical COVID-19 patients. Interim results relate to eight patients, six of whom were in severe condition and two of whom were in critical condition.
  • Data showed that 7 patients treated through November 26 had complete recovery from their respective severe/critical condition and were discharged from the hospital, after an average of 4.7 days following Allocetra administration.
  • The eighth enrolled after 27 Nov. experienced a clinical improvement following Allocetra treatment, but remained hospitalized six days after treatment.
  • Taken together with previously-treated patients in Phase Ib study, all 12 patients through November 26 had complete recovery and were discharged, after an average of 5.5 days following Allocetra administration.
  • Overall Allocetra was well tolerated with no treatment-related serious adverse events.
  • https://seekingalpha.com/news/3641329-enlivex-therapeutics-rises-on-interim-allocetra-data-in-mid-stage-covidminus-19-study

Avid Bioservices Q2 Earnings

 Shares of Avid Bioservices (NASDAQ:CDMO) moved higher after the company reported Q2 results.

Quarterly Results

Earnings per share were up 133.33% over the past year to $0.01, which beat the estimate of ($0.06).

Revenue of $21,064,000 up by 15.02% from the same period last year, which beat the estimate of $15,490,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Dec 02, 2020

View more earnings on CDMO

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/jok7k959

Price Action

Company's 52-week high was at $9.37

52-week low: $3.02

Price action over last quarter: Up 11.76%

Company Profile

Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on development and current Good Manufacturing Practices (cGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.

https://finance.yahoo.com/news/recap-avid-bioservices-q2-earnings-211940658.html

South Korea reaches deal to buy AstraZeneca's COVID-19 vaccine candidate

 

South Korea has reached a deal with AstraZeneca PLC to purchase its coronavirus vaccine candidate as it seeks to secure supplies amid a resurgence of outbreaks, local media reported on Thursday.

The government has said it was in final talks with global drugmakers including AstraZeneca, Pfizer Inc and Johnson & Johnson over their experimental vaccines, and launched a preliminary review of AstraZeneca's product in October for potential fast-track approval.

The JoongAng Ilbo newspaper said health authorities signed a contract with the Britain-based company on Nov. 27, and were nearing agreements with Pfizer and Johnson & Johnson, citing an unidentified government official.

"The AstraZeneca deal has been done, and a memorandum of understanding was reached with both Pfizer and Johnson & Johnson. But further negotiations are needed to finalise the amount of supplies and the timing of shipment," the official was quoted as saying.

The Yonhap news agency also reported, citing an unnamed health official, that an agreement with AstraZeneca was inked recently and the government would make an announcement as early as next week after completing negotiations with other firms.

The Korea Disease Control and Prevention Agency (KDCA) said that the JoongAng report was not the government's official position but that it would finalise talks and unveil comprehensive results shortly.

The KDCA has said 172 billion won ($157 million) was set aside to buy an initial 60 million doses this year, enough to vaccinate about 60% of the country's population of 52 million, around the second quarter of 2021.

It has secured 20 million doses via the COVAX facility, an international COVID-19 vaccine allocation platform co-led by the WHO.

https://www.marketscreener.com/quote/stock/ASTRAZENECA-PLC-4000930/news/AstraZeneca-South-Korea-reaches-deal-to-buy-AstraZeneca-s-COVID-19-vaccine-candidate-media-31925690/

Merck Enters Research Agreement With Artios on Precision Oncology

 Merck KGaA said Thursday that it is to collaborate with U.K. DNA damage-response company Artios Pharma on research to discover and develop multiple precision-oncology drugs.

Under the three-year agreement, Artios will receive $30 million in up-front and near-term payments, Merck said. The German pharmaceutical company added that it will have the right to opt into development and commercialization of compounds on up to eight targets. Artios could then receive a further $860 million in milestone payments, as well as up to double-digit royalties on net sales of each product.

The companies will together use Artios's proprietary nuclease-targeting discovery platform to identify multiple targets for precision cancer-treatment candidates, Merck said. The terms of the agreement don't cover Artios's lead programs, for which it will retain all rights.

https://www.marketscreener.com/quote/stock/MERCK-KGAA-436395/news/Merck-Enters-Research-Agreement-With-Artios-on-Precision-Oncology-Treatments-31926762/

Inovio adds new member to manufacturing group for COVID-19 vaccine

 

WHO looks at possible 'e-vaccination certificates' for travel

 The World Health Organization does not recommend countries issuing “immunity passports” for those who have recovered from COVID-19, but is investigating the prospects of using e-vaccination certificates, a WHO medical expert said on Thursday.

“We are looking very closely into the use of technology in this COVID-19 response, one of them how we can work with member states toward an e-vaccination certificate,” he told a virtual briefing in Copenhagen.

https://www.reuters.com/article/us-health-coronavirus-who-passports/who-looks-at-possible-e-vaccination-certificates-for-travel-idUSKBN28D1J4

IBM warns hackers targeting COVID vaccine 'cold chain' supply process

 IBM is sounding the alarm over hackers targeting companies critical to the distribution of COVID-19 vaccines, a sign that digital spies are turning their attention to the complex logistical work involved in inoculating the world’s population against the novel coronavirus.

The information technology company said in a blog post published on Thursday that it had uncovered “a global phishing campaign” focused on organizations associated with the COVID-19 vaccine “cold chain” - the process needed to keep vaccine doses at extremely cold temperatures as they travel from manufacturers to people’s arms.

The U.S. Cybersecurity and Infrastructure Security Agency reposted the report, warning members of Operation Warp Speed - the U.S. government’s national vaccine mission - to be on the lookout. Understanding how to build a secure cold chain is fundamental to distributing vaccines developed by the likes of Pfizer Inc and BioNTech SE because the shots need to be stored at minus 70 degrees Celsius (-94 F) or below to avoid spoiling.

IBM’s cybersecurity unit said it had detected an advanced group of hackers working to gather information about different aspects of the cold chain, using meticulously crafted booby-trapped emails sent in the name of an executive with Haier Biomedical, a Chinese cold chain provider that specializes in vaccine transport and biological sample storage.

The hackers went through “an exceptional amount of effort,” said IBM analyst Claire Zaboeva, who helped draft the report. Hackers researched the correct make, model, and pricing of various Haier refrigeration units, Zaboeva said.

“Whoever put together this campaign was intimately aware of whatever products were involved in the supply chain to deliver a vaccine for a global pandemic,” she said.

Haier Medical did not return messages seeking comment.

Messages sent to the email addresses used by the hackers were not returned.

IBM said the bogus Haier emails were sent to around 10 different organizations but only identified one target by name: the European Commission’s Directorate-General for Taxation and Customs Union, which handles tax and customs issues across the EU and has helped set rules on the import of vaccines.

Representatives for the directorate-general could not immediately be reached for comment.

IBM said other targets included companies involved in the manufacture of solar panels, which are used to power vaccine refrigerators in warm countries, and petrochemical products that could be used to derive dry ice.

Who is behind the vaccine supply chain espionage campaign isn’t clear.

Reuters has previously documented how hackers linked to Iran, Vietnam, North Korea, South Korea, China, and Russia have on separate occasions been accused by cybersecurity experts or government officials of trying to steal information about the virus and its potential treatments.

IBM’s Zaboeva said there was no shortage of potential suspects. Figuring out how to swiftly distribute an economy-saving vaccine “should be topping the lists of nation states across the world,” she said.

https://www.reuters.com/article/us-health-coronavirus-vaccines-cyber/ibm-warns-hackers-targeting-covid-vaccine-cold-chain-supply-process-idUSKBN28D191